Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SCOLR controlled-delivery drugs

This article was originally published in The Tan Sheet

Executive Summary

SCOLR Pharma plans to develop 24-hour OTC pseudoephedrine decongestant and12-hour OTC combination ibuprofen/pseudoephedrine cough/cold products using the company's controlled delivery technology (CDT) platform, the firm says April 13. All three products are in the preclinical stages of development. The Bellevue, Wash.-based firm recently announced positive results from trials on 12-hour CDT pseudoephedrine and ibuprofen products and intends to submit both for FDA approval this summer (1"The Tan Sheet" April 4, 2005, p. 15)...

You may also be interested in...

Extended-Release Pseudoephedrine Trial Results “Positive,” SCOLR Says

The first of three human studies evaluating SCOLR Pharma's extended-release pseudoephedrine tablets has shown "positive" initial results, the company announced March 28

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts